Strategic Partnerships CaroGen has an exclusive license with Yale University for replication-proficient virus-like vesicle VLV platform, presenting a high-potential collaboration angle for contract development, licensing discussions, or co-development deals with biotech firms and academic partners seeking novel vaccine technologies.

Early Stage Vetting With a small team and early-stage portfolio targeting HBV and other infectious diseases, there is an opportunity to engage in pilot projects, sponsored research, or consulting services to help shape preclinical strategies, regulatory planning, and manufacturing readiness.

Manufacturing Alliances Recent manufacturing partnerships such as with BioCentriq indicate a pathway for CRO/CDMO collaboration. Target mid-market manufacturers and contract services that can support scale-up, analytics, and GMP production for CARG-201 and other vaccine candidates.

Clinical & Preclinical Strategic outreach to government and research institutions (NIH NIAID collaborations) suggests opportunities for funding-aligned projects, preclinical program support, and access to external validation channels to accelerate vaccine candidates.

Investor & Communications Despite being small, CaroGen has demonstrated recognitions and media presence. Leverage this narrative in investor-focused materials, grant applications, and partnership pitches to highlight momentum, platform uniqueness, and potential first-in-class vaccines.